IL-6 is often associated with the tumour microenvironment [26] and clinically, circulating IL-6 level is associated with poor prognosis and low survival rate in patients with breast cancer [27], while IL-6 polymorphisms are linked to increased breast cancer risk [28]. This evidence concerns the gene IL6 and neoplasm.